BS_HZE3KYZ1
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 58.31143232588699
- age_years
- 15.523
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.555
- MYC_TARGETS_V2+0.488
- E2F_TARGETS+0.447
- G2M_CHECKPOINT+0.444
- DNA_REPAIR+0.311
- UNFOLDED_PROTEIN_RESPONSE+0.212
- MITOTIC_SPINDLE+0.153
- OXIDATIVE_PHOSPHORYLATION+0.130
- SPERMATOGENESIS+0.095
- PROTEIN_SECRETION+0.077
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.623
- INTERFERON_GAMMA_RESPONSE-0.575
- IL6_JAK_STAT3_SIGNALING-0.483
- TNFA_SIGNALING_VIA_NFKB-0.469
- NOTCH_SIGNALING-0.463
- INFLAMMATORY_RESPONSE-0.462
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.451
- ANGIOGENESIS-0.450
- CHOLESTEROL_HOMEOSTASIS-0.450
- HYPOXIA-0.447
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_K74PZET7 | medulloblastoma | — | 0.979 |
| 2 | BS_JFB984RG | medulloblastoma | — | 0.977 |
| 3 | BS_HF3RNN2T | medulloblastoma | — | 0.972 |
| 4 | BS_G00FHF3Q | medulloblastoma | — | 0.970 |
| 5 | BS_Z7PKVY9J | medulloblastoma | — | 0.968 |
| 6 | BS_DFWFBYSN | medulloblastoma | — | 0.967 |
| 7 | BS_BSV07M7Z | medulloblastoma | — | 0.967 |
| 8 | BS_QHS3V0GP | Embryonal tumors | — | 0.966 |
| 9 | BS_TZVFR600 | medulloblastoma | — | 0.965 |
| 10 | BS_Y8D1F5WW | medulloblastoma | — | 0.964 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.555 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.488 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.447 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.444 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.311 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.212 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.153 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.095 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.077 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.053 | Cobimetinib | — uncovered |